Leucine-rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease

Journal of Neuroscience Research

Volumn 87, Issue 6, 2009, Pages 1283-1295

  Gandhi, Payal N ^a   Chen, Shu G ^b   Wilson Delfosse, Amy L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Leucine rich repeat kinase 2 (LRRK2); Neurodegeneration; Parkinson's disease; Signal transduction

Indexed keywords

ALPHA SYNUCLEIN; AMINO ACID; DJ 1 PROTEIN; GLYCINE; GUANOSINE TRIPHOSPHATASE; LEUCINE RICH REPEAT KINASE 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PARKIN; PROTEIN KINASE; SERINE; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

AMINO ACID SUBSTITUTION; AUTOSOMAL DOMINANT DISORDER; DEGENERATIVE DISEASE; ENZYME ACTIVITY; GENETIC CODE; HUMAN; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NEUROPATHOLOGY; NONHUMAN; ORTHOLOGY; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BRAIN; CHEMISTRY; GENETICS; METABOLISM; MUTATION; PATHOLOGY;

ANIMALS; BRAIN; HUMANS; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 65549124540     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21949     Document Type: Review

References (135)

1. Aasly JO, Toft M, Fernandez-Mata I, Kachergus J, Hulihan M, White LR, Farrer M. 2005. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol 57:762-765.
2. Adams JR, van Netten H, Schulzer M, Mak E, McKenzie J, Strongosky A, Sossi V, Ruth TJ, Lee CS, Farrer M, Gasser T, Uitti RJ, Calne DB, Wszolek ZK, Stoessl AJ. 2005. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 128:2777-2785.
3. Alegre-Abarrategui J, Ansorge O, Esiri M, Wade-Martins R. 2008. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Neuropathol Appl Neurobiol 34:272-283.
4. Berg D, Leitner P, Zimprich A, Lichtner P, Belcredi P, Brussel T, Schulte C, Maass S, Nagele T. 2005. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease. Brain 128:3000-3011.
5. Bialecka M, Hui S, Klodowska-Duda G, Opala G, Tan EK, Drozdzik M. 2005. Analysis of LRRK 2 G 2019 S and I 2020 T mutations in Parkinson's disease. Neurosci Lett 390:1-3.
6. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, Kurkinen K, Yu SW, Savitt JM, Waldvogel HJ, Faull RL, Emson PC, Torp R, Ottersen OP, Dawson TM, Dawson VL. 2006. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 60:557-569.
7. Bonifati V. 2006. Parkinson's disease: the LRRK2-G2019S mutation: opening a novel era in Parkinson's disease genetics. Eur J Hum Genet 14:1061-1062.
8. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, Heutink P. 2003. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299:256-259.
9. Bosgraaf L. 2003. Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys Acta 1643:5-10.
10. Bras JM, Guerreiro RJ, Ribeiro MH, Januario C, Morgadinho A, Oliveira CR, Cunha L, Hardy J, Singleton A. 2005. G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort. Mov Disord 20:1653-1655.
11. Bretscher A, Edwards K, Fehon RG. 2002. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 3:586599.
12. Brown DA, London E. 1998. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 14:111-136.
13. Carmine Belin A, Westerlund M, Sydow O, Lundstromer K, Hakansson A, Nissbrandt H, Olson L, Galter D. 2006. Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian. Mov Disord 21:1731-1734.
14. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destee A. 2004. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364:1167-1169.
15. Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, Ross CA, Dawson VL, Dawson TM. 2001. Parkin ubiquitinates the alpha-synuclein- interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med 7:1144-1150.
16. Clarimon J, Pagonabarraga J, Paisan-Ruiz C, Campolongo A, Pascual- Sedano B, Marti-Masso JF, Singleton AB, Kulisevsky J. 2008. Tremor dominant parkinsonism: clinical description and LRRK2 mutation screening. Mov Disord 23:518-523.
17. Clark LN, Wang Y, Karlins E, Saito L, Mejia-Santana H, Harris J, Louis ED, Cote LJ, Andrews H, Fahn S, Waters C, Ford B, Frucht S, Ottman R, Marder K. 2006. Frequency of LRRK2 mutations in earlyand late-onset Parkinson disease. Neurology 67:1786-1791.
18. Cookson MR. 2005. The biochemistry of Parkinson's disease. Annu Rev Biochem 74:29-52.
19. Dachsel JC, Mata IF, Ross OA, Taylor JP, Lincoln SJ, Hinkle KM, Huerta C, Ribacoba R, Blazquez M, Alvarez V, Farrer MJ. 2006. Digenic parkinsonism: investigation of the synergistic effects of PRKN and LRRK2. Neurosci Lett 410:80-84.
20. Dachsel JC, Taylor JP, Mok SS, Ross OA, Hinkle KM, Bailey RM, Hines JH, Szutu J, Madden B, Petrucelli L, Farrer MJ. 2007. Identification of potential protein interactors of Lrrk2. Parkinsonism Rel Disord 13:382-385.
21. Dauer W, Przedborski S. 2003. Parkinson's disease: mechanisms and models. Neuron 39:889-909.
22. Deng J, Lewis PA, Greggio E, Sluch E, Beilina A, Cookson MR. 2008. Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci U S A 105:1499-1504.
23. Di Fonzo A, De Mari M, Chien HF, Ferreira J, Rohe CF, Riboldazzi G, Antonini A, Albani G, Mauro A, Marconi R, Abbruzzese G, Lopiano L, Fincati E, Guidi M, Marini P, Stocchi F, Onofrj M, Toni V, Tinazzi M, Fabbrini G, Lamberti P, Vanacore N, Meco G, Leitner P, Uitti RJ, Wszolek ZK, Gasser T, Simons EJ, Breedveld GJ, Goldwurm S, Pezzoli G, Sampaio C, Barbosa E, Martignoni E, Oostra BA, Bonifati V;Italian Parkinson's Genetics Network. 2006a. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet 14:322-331.
24. Di Fonzo A, Wu-Chou YH, Lu CS, van Doeselaar M, Simons EJ, Rohe CF, Chang HC, Chen RS, Weng YH, Vanacore N, Breedveld GJ, Oostra BA, Bonifati V. 2006b. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 7:133-138.
25. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. 2007. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68:384-386.
26. Farrer MJ, Stone JT, Lin CH, Dachsel JC, Hulihan MM, Haugarvoll K, Ross OA, Wu RM. 2007. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Rel Disord 13:89-92.
27. Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, Kowa H, Tsuji S, Obata F. 2005. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 57:918-921.
28. Fung HC, Chen CM, Hardy J, Hernandez D, Singleton A, Wu YR. 2006a. Lack of G2019S LRRK2 mutation in a cohort of Taiwanese with sporadic Parkinson's disease. Mov Disord 21:880-881.
29. Fung HC, Chen CM, Hardy J, Singleton AB, Wu YR. 2006b. A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan. BMC Neurol 6:47.
30. Futey LM, Medley QG, Cote GP, Egelhoff TT. 1995. Structural analysis of myosin heavy chain kinase A from Dictyostelium. Evidence for a highly divergent protein kinase domain, an amino-terminal coiled-coil domain, and a domain homologous to the beta-subunit of heterotrimeric G proteins. J Biol Chem 270:523-529.
31. Gaig C, Ezquerra M, Marti MJ, Munoz E, Valldeoriola F, Tolosa E. 2006. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol 63:377-382.
32. Galter D, Westerlund M, Carmine A, Lindqvist E, Sydow O, Olson L. 2006. LRRK2 expression linked to dopamine-innervated areas. Ann Neurol 59:714-719.
33. Galter D, Westerlund M, Belin AC, Olson L. 2007. DJ-1 and UCH-L1 gene activity patterns in the brains of controls, Parkinson and schizophrenia patients and in rodents. Physiol Behav 92:46-53.
34. Gandhi PN, Wang X, Zhu X, Chen SG, Wilson-Delfosse AL. 2008. The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J Neurosci Res 86:1711-1720.
35. Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ, Van Deerlin VM. 2006. Biochemical and pathological characterization of Lrrk2. Ann Neurol 59:315-322.
36. Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, Meitinger T, Kolch W, Prokisch H, Ueffing M. 2006. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15:223-232 [E-pub December 2005].
37. Goldwurm S, Di Fonzo A, Simons EJ, Rohe CF, Zini M, Canesi M, Tesei S, Zecchinelli A, Antonini A, Mariani C, Meucci N, Sacilotto G, Sironi F, Salani G, Ferreira J, Chien HF, Fabrizio E, Vanacore N, Dalla Libera A, Stocchi F, Diroma C, Lamberti P, Sampaio C, Meco G, Barbosa E, Bertoli-Avella AM, Breedveld GJ, Oostra BA, Pezzoli G, Bonifati V. 2005. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet 42:e65.
38. Goldwurm S, Zini M, Di Fonzo A, De Gaspari D, Siri C, Simons EJ, van Doeselaar M, Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani C, Meucci N, Sacilotto G, Cilia R, Isaias IU, Bonetti A, Sironi F, Ricca S, Oostra BA, Bonifati V, Pezzoli G. 2006. LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Parkinsonism Rel Disord 12:410-419.
39. Goldwurm S, Zini M, Mariani L, Tesei S, Miceli R, Sironi F, Clementi M, Bonifati V, Pezzoli G. 2007. Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. Neurology 68:1141-1143.
40. Gotthardt K, Weyand M, Kortholt A, Van Haastert PJ, Wittinghofer A. 2008. Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase. EMBO J 27:2352.
41. Grammatikakis N, Lin JH, Grammatikakis A, Tsichlis PN, Cochran BH. 1999. p50(cdc37) Acting in concert with Hsp90 is required for Raf-1 function. Mol Cell Biol 19:1661-1672.
42. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ, Ahmad R, Miller DW, Kesavapany S, Singleton A, Lees A, Harvey RJ, Harvey K, Cookson MR. 2006. Kinase activity is required for the toxic effects of mutant LRRK2/ dardarin. Neurobiol Dis 23:329-341.
43. Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, Daniels V, Lewis P, Jain S, Ding J, Syed A, Thomas KJ, Baekelandt V, Cookson MR. 2008. The Parkinson's disease associated Leucine rich repeat kinase 2 (LRRK2) is a dimer that undergoes intra-molecular autophosphorylation. J Biol Chem 283:16906-16914.
44. Guo L, Wang W, Chen SG. 2006. Leucine-rich repeat kinase 2: relevance to Parkinson's disease. Int J Biochem Cell Biol 38:1469-1475.
45. Guo L, Gandhi PN, Wang W, Petersen RB, Wilson-Delfosse AL, Chen SG. 2007. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res 313:3658-3670.
46. Habig K, Walter M, Poths S, Riess O, Bonin M. 2008. RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player. Neurogenetics 9:83-94.
47. Hatano T, Kubo S, Imai S, Maeda M, Ishikawa K, Mizuno Y, Hattori N. 2007. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet 16:678-690.
48. Haugarvoll K, Rademakers R, Kachergus JM, Nuytemans K, Ross OA, Gibson JM, Tan EK, Gaig C, Tolosa E, Goldwurm S, Guidi M, Riboldazzi G, Brown L, Walter U, Benecke R, Berg D, Gasser T, Theuns J, Pals P, Cras P, De Deyn PP, Engelborghs S, Pickut B, Uitti RJ, Foroud T, Nichols WC, Hagenah J, Klein C, Samii A, Zabetian CP, Bonifati V, Van Broeckhoven C, Farrer MJ, Wszolek ZK. 2008. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 70:1456-1460.
49. Hernandez D, Crawley A, Malkani R, Werner J, Gwinn-Hardy K, Dickson D, Wavrant Devrieze F, Hardy J, Singleton A. 2005. The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. Neurosci Lett 389:137-139.
50. Higashi S, Biskup S, West AB, Trinkaus D, Dawson VL, Faull RL, Waldvogel HJ, Arai H, Dawson TM, Moore DJ, Emson PC. 2007a. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res 1155:208-219.
51. Higashi S, Moore DJ, Colebrooke RE, Biskup S, Dawson VL, Arai H, Dawson TM, Emson PC. 2007b. Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. J Neurochem 100:368-381.
52. Ho GJ, Drego R, Hakimian E, Masliah E. 2005. Mechanisms of cell signaling and inflammation in Alzheimer's disease. Curr Drug Targets Inflamm Allergy 4:247-256.
53. Huang L, Wong TY, Lin RC, Furthmayr H. 1999. Replacement of threonine 558, a critical site of phosphorylation of moesin in vivo, with aspartate activates F-actin binding of moesin. Regulation by conformational change. J Biol Chem 274:12803-12810.
54. Iaccarino C, Crosio C, Vitale C, Sanna G, Carri MT, Barone P. 2007. Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet 16:1319-1326.
55. Infante J, Rodriguez E, Combarros O, Mateo I, Fontalba A, Pascual J, Oterino A, Polo JM, Leno C, Berciano J. 2006. LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease. Neurosci Lett 395:224-226.
56. Ito G, Okai T, Fujino G, Takeda K, Ichijo H, Katada T, Iwatsubo T. 2007. GTP Binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 46:1380-1388.
57. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, Alessi DR. 2007. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405:307-317.
58. Janda L, Tichy P, Spizek J, Petricek M. 1996. A deduced Thermomonospora curvata protein containing serine/threonine protein kinase and WD-repeat domains. J Bacteriol 178:1487-1489.
59. Johnson JE. 2003. Numb and Numblike control cell number during vertebrate neurogenesis. Trends Neurosci 26:395-396.
60. Johnson J, Paisan-Ruiz C, Lopez G, Crews C, Britton A, Malkani R, Evans EW, McInerney-Leo A, Jain S, Nussbaum RL, Foote KD, Mandel RJ, Crawley A, Reimsnider S, Fernandez HH, Okun MS, Gwinn-Hardy K, Singleton AB. 2007. Comprehensive screening of a North American Parkinson's disease cohort for LRRK2 mutation. Neurodegener Dis 4:386-391.
61. Kachergus J, Hulihan M, Taylor JP, Lincoln S, Aasly J, Gibson JM, Ross OA, Lynch T, Wiley J, Payami H, Nutt J, Maraganore DM, Czyzewski K, Styczynska M, Wszolek ZK, Farrer MJ, Toft M. 2005. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 76:672-680.
62. Kalinderi K, Fidani L, Bostantjopoulou S, Katsarou Z, Kotsis A. 2007. The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson's disease. Eur J Neurol 14:1088-1090.
63. Kay DM, Zabetian CP, Factor SA, Nutt JG, Samii A, Griffith A, Bird TD, Kramer P, Higgins DS, Payami H. 2006. Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics. Mov Disord 21:519-523.
64. Khan NL, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, Healy DG, Gilks WP, Sweeney MG, Ganguly M, Gibbons V, Gandhi S, Vaughan J, Eunson LH, Katzenschlager R, Gayton J, Lennox G, Revesz T, Nicholl D, Bhatia KP, Quinn N, Brooks D, Lees AJ, Davis MB, Piccini P, Singleton AB, Wood NW. 2005. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 128:2786-2796.
65. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608.
66. Kobe B, Deisenhofer J. 1995. Proteins with leucine-rich repeats. Curr Opin Struct Biol 5:409-416.
67. Kyosseva SV. 2004. Mitogen-activated protein kinase signaling. Int Rev Neurobiol 59:201-220.
68. Lee SB, Kim W, Lee S, Chung J. 2007. Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila. Biochem Biophys Res Commun 358:534-539.
69. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Polymeropoulos MH. 1998. The ubiquitin pathway in Parkinson's disease. Nature 395:451-452.
70. Lesage S, Leutenegger AL, Ibanez P, Janin S, Lohmann E, Durr A, Brice A. 2005. LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am J Hum Genet 77:330-332.
71. Lesage S, Durr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, Pollak P, Brice A. 2006. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 354:422-423.
72. Lewis PA, Greggio E, Beilina A, Jain S, Baker A, Cookson MR. 2007. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun 357:668-671.
73. Li X, Tan YC, Poulose S, Olanow CW, Huang XY, Yue Z. 2007. Leucine- rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem 103:238-247.
74. Liu Z, Wang X, Yu Y, Li X, Wang T, Jiang H, Ren Q, Jiao Y, Sawa A, Moran T, Ross CA, Montell C, Smith WW. 2008. A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A 105:2693-2698.
75. Lu CS, Simons EJ, Wu-Chou YH, Fonzo AD, Chang HC, Chen RS, Weng YH, Rohe CF, Breedveld GJ, Hattori N, Gasser T, Oostra BA, Bonifati V. 2005. The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease. Parkinsonism Rel Disord 11:521-522.
76. Luzon-Toro B, de la Torre ER, Delgado A, Perez-Tur J, Hilfiker S. 2007. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Hum Mol Genet 16:2031-2039.
77. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A. 2006. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52:587-593.
78. Manning G, Martinez R, Hunter T, Sudarsanam S. 2002. The protein kinase complement of the human genome. Science 298:1912-1934.
79. Marin I. 2006. The Parkinson disease gene LRRK2: evolutionary and structural insights. Mol Biol Evol 23:2423-2433.
80. Mata IF, Taylor JP, Lincoln S, Aasly J, Lynch T, Hulihan MM, Cobb SA, Wu RM, Lu CS, Lahoz C, Wszolek ZK, Farrer MJ. 2005. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 6:171-177 [E-pub September 2005].
81. Mata IF, Ross OA, Kachergus J, Huerta C, Ribacoba R, Moris G, Blazquez M, Guisasola LM, Salvador C, Martinez C, Farrer M, Alvarez V. 2006a. LRRK2 mutations are a common cause of Parkinson's disease in Spain. Eur J Neurol 13:391-394.
82. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA. 2006b. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci 29:286-293.
83. Melrose H, Lincoln S, Tyndall G, Dickson D, Farrer M. 2006. Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience 139:791-794.
84. Melrose HL, Kent CB, Taylor JP, Dachsel JC, Hinkle KM, Lincoln SJ, Mok SS, Culvenor JG, Masters CL, Tyndall GM, Bass DI, Ahmed Z, Andorfer CA, Ross OA, Wszolek ZK, Delldonne A, Dickson DW, Farrer MJ. 2007. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 147:1047-1058.
85. Meylan J. 2005. The RIP kinases: crucial integrators of cellular stress. Trends Biochem Sci 30:151-159.
86. Nichols WC, Elsaesser VE, Pankratz N, Pauciulo MW, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T. 2007. LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. Neurology 69:1737-1744.
87. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt AL, Klein C, Henick B, Hailpern SM, Lipton RB, Soto-Valencia J, Risch N, Bressman SB. 2006. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 354:424-425.
88. Paglini G, Kunda P, Quiroga S, Kosik K, Caceres A. 1998. Suppression of radixin and moesin alters growth cone morphology, motility, and process formation in primary cultured neurons. J Cell Biol 143:443-455.
89. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB. 2004. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44:595-600.
90. Paisan-Ruiz C, Lang AE, Kawarai T, Sato C, Salehi-Rad S, Fisman GK, Al-Khairallah T, St. George-Hyslop P, Singleton A, Rogaeva E. 2005. LRRK2 gene in Parkinson disease: mutation analysis and case control association study. Neurology 65:696-700.
91. Paisan-Ruiz C, Evans EW, Jain S, Xiromerisiou G, Gibbs JR, Eerola J, Gourbali V, Hellstrom O, Duckworth J, Papadimitriou A, Tienari PJ, Hadjigeorgiou GM, Singleton AB. 2006. Testing association between LRRK2 and Parkinson's disease and investigating linkage disequilibrium. J Med Genet 43:e9.
92. Paisan-Ruiz C, Nath P, Washecka N, Gibbs JR, Singleton AB. 2008. Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls. Hum Mutat 29:485-490.
93. Pchelina SN, Yakimovskii AF, Ivanova ON, Emelianov AK, Zakharchuk AH, Schwarzman AL. 2006. G2019S LRRK2 mutation in familial and sporadic Parkinson's disease in Russia. Mov Disord 21:2234-2236.
94. Perry G, Zhu X, Babar AK, Siedlak SL, Yang Q, Ito G, Iwatsubo T, Smith MA, Chen SG. 2008. Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies. Neurodegener Dis 5:222-224.
95. Plowey ED, Cherra SJ 3rd, Liu YJ, Chu CT. 2008. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SHSY5Y cells. J Neurochem 105:1048-1056.
96. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047.
97. Punia S, Behari M, Govindappa ST, Swaminath PV, Jayaram S, Goyal V, Muthane UB, Juyal RC, Thelma BK. 2006. Absence/rarity of commonly reported LRRK2 mutations in Indian Parkinson's disease patients. Neurosci Lett 409:83-88.
98. Ross OA, Wu YR, Lee MC, Funayama M, Chen ML, Soto AI, Mata IF, Lee-Chen GJ, Chen CM, Tang M, Zhao Y, Hattori N, Farrer MJ, Tan EK, Wu RM. 2008. Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neurol 64:88-92.
99. Sakaguchi-Nakashima A, Meir JY, Jin Y, Matsumoto K, Hisamoto N. 2007. LRK-1, a C. elegans PARK8-related kinase, regulates axonaldendritic polarity of SV proteins. Curr Biol 17:592-598.
100. Schlossmacher MG, Frosch MP, Gai WP, Medina M, Sharma N, Forno L, Ochiishi T, Shimura H, Sharon R, Hattori N, Langston JW, Mizuno Y, Hyman BT, Selkoe DJ, Kosik KS. 2002. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol 160:1655-1667.
101. Schulz JB, Falkenburger BH. 2004. Neuronal pathology in Parkinson's disease. Cell Tissue Res 318:135-147.
102. Shin N, Jeong H, Kwon J, Heo HY, Kwon JJ, Yun HJ, Kim CH, Han BS, Tong Y, Shen J, Hatano T, Hattori N, Kim KS, Chang S, Seol W. 2008. LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res 314:2055-2065.
103. Silva RM, Kuan CY, Rakic P, Burke RE. 2005. Mixed lineage kinasec- jun N-terminal kinase signaling pathway: a new therapeutic target in Parkinson's disease. Mov Disord 20:653-664.
104. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. 2003. Alpha-synuclein locus triplication causes Parkinson's disease. Science 302:841.
105. Skipper L, Li Y, Bonnard C, Pavanni R, Yih Y, Chua E, Sung WK, Tan L, Wong MC, Tan EK, Liu J. 2005. Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson's disease. Hum Mol Genet 14:3549-3556.
106. Smith TF, Gaitatzes C, Saxena K, Neer EJ. 1999. The WD repeat: a common architecture for diverse functions. Trends Biochem Sci 24:181-185.
107. Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, Dawson VL, Dawson TM, Ross CA. 2005. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A 102:18676-18681 [E-pub December 2005].
108. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. 2006. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9:1231-1233.
109. Solano SM, Miller DW, Augood SJ, Young AB, Penney JB Jr. 2000. Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease. Ann Neurol 47:201-210.
110. Spanaki C, Latsoudis H, Plaitakis A. 2006. LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP. Neurology 67:1518-1519.
111. Stenmark P, Ogg D, Flodin S, Flores A, Kotenyova T, Nyman T, Nordlund P, Kursula P. 2007. The structure of human collapsin response mediator protein 2, a regulator of axonal growth. J Neurochem 101:906-917.
112. Takahashi K, Sasaki T, Mammoto A, Takaishi K, Kameyama T, Tsukita S, Takai Y. 1997. Direct interaction of the Rho GDP dissociation inhibitor with ezrin/radixin/moesin initiates the activation of the Rho small G protein. J Biol Chem 272:23371-23375.
113. Tan EK, Shen H, Tan LC, Farrer M, Yew K, Chua E, Jamora RD, Puvan K, Puong KY, Zhao Y, Pavanni R, Wong MC, Yih Y, Skipper L, Liu JJ. 2005. The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. Neurosci Lett 384:327-329.
114. Tan EK, Lee J, Chen CP, Wong MC, Zhao Y. 2007a. Case control analysis of LRRK2 Gly2385Arg in Alzheimer's disease. Neurobiol Aging (in press).
115. Tan EK, Zhao Y, Skipper L, Tan MG, Di Fonzo A, Sun L, Fook- Chong S, Tang S, Chua E, Yuen Y, Tan L, Pavanni R, Wong MC, Kolatkar P, Lu CS, Bonifati V, Liu JJ. 2007b. The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum Genet 120:857-863.
116. Tan EK, Tan LC, Lim HQ, Li R, Tang M, Yih Y, Pavanni R, Prakash KM, Fook-Chong S, Zhao Y. 2008. LRRK2 R1628P increases risk of Parkinson's disease: replication evidence. Hum Genet 124:287-288.
117. Taylor JP, Farrer MJ. 2006. LRRK2: a common pathway for parkinsonism, pathogenesis and prevention? Trends Mol Med 12:76-82.
118. Taymans JM, Van den Haute C, Baekelandt V. 2006. Distribution of PINK1 and LRRK2 in rat and mouse brain. J Neurochem 98:951-961.
119. Toft M, Sando SB, Melquist S, Ross OA, White LR, Aasly JO, Farrer MJ. 2005. LRRK2 mutations are not common in Alzheimer's disease. Mech Ageing Dev 126:1201-1205.
120. Tomiyama H, Li Y, Funayama M, Hasegawa K, Yoshino H, Kubo S, Sato K, Hattori T, Lu CS, Inzelberg R, Djaldetti R, Melamed E, Amouri R, Gouider-Khouja N, Hentati F, Hatano Y, Wang M, Imamichi Y, Mizoguchi K, Miyajima H, Obata F, Toda T, Farrer MJ, Mizuno Y, Hattori N. 2006. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. Mov Disord 21:1102-1108.
121. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalez-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW. 2004. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304:1158-1160.
122. Wang D, Tang B, Zhao G, Pan Q, Xia K, Bodmer R, Zhang Z. 2008. Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons. Mol Neurodegener 3:3.
123. Wang L, Xie C, Greggio E, Parisiadou L, Shim H, Sun L, Chandran J, Lin X, Lai C, Yang WJ, Moore DJ, Dawson TM, Dawson VL, Chiosis G, Cookson MR, Cai H. 2008. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci 28:3384-3391.
124. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM. 2005. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102:16842-16847 [E-pub November 2005].
125. West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL, Dawson TM. 2007. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16:223-232.
126. White LR, Toft M, Kvam SN, Farrer MJ, Aasly JO. 2007. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease. J Neurosci Res 85:1288-1294.
127. Williams-Gray CH, Goris A, Foltynie T, Brown J, Maranian M, Walton A, Compston DA, Sawcer SJ, Barker RA. 2006. Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort. J Neurol Neurosurg Psychiatry 77:665-667.
128. Wolozin B, Saha S, Guillily M, Ferree A, Riley M. 2008. Investigating convergent actions of genes linked to familial Parkinson's disease. Neurodegen Dis 5:182-185.
129. Xiromerisiou G, Hadjigeorgiou GM, Gourbali V, Johnson J, Papakonstantinou I, Papadimitriou A, Singleton AB. 2007. Screening for SNCA and LRRK2 mutations in Greek sporadic and autosomal dominant Parkinson's disease: identification of two novel LRRK2 variants. Eur J Neurol 14:7-11.
130. Zabetian CP, Hutter CM, Yearout D, Lopez AN, Factor SA, Griffith A, Leis BC, Bird TD, Nutt JG, Higgins DS, Roberts JW, Kay DM, Edwards KL, Samii A, Payami H. 2006a. LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet 79:752-758.
131. Zabetian CP, Morino H, Ujike H, Yamamoto M, Oda M, Maruyama H, Izumi Y, Kaji R, Griffith A, Leis BC, Roberts JW, Yearout D, Samii A, Kawakami H. 2006b. Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease. Neurology 67:697-699.
132. Zhang H, Wu W, Du Y, Santos SJ, Conrad SE, Watson JT, Grammatikakis N, Gallo KA. 2004. Hsp90/p50cdc37 is required for mixed-lineage kinase (MLK) 3 signaling. J Biol Chem 279:19457-19463.
133. Zhu X, Babar A, Siedlak SL, Yang Q, Ito G, Iwatsubo T, Smith MA, Perry G, Chen SG. 2006a. LRRK2 in Parkinson's disease and dementia with Lewy bodies. Mol Neurodegen 1:17.
134. Zhu X, Siedlak SL, Smith MA, Perry G, Chen SG. 2006b. LRRK2 protein is a component of lewy bodies. Ann Neurol 59:388-393.
135. Zimprich A, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T. 2004. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601-607.